Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp.
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
sitagliptin +simvastatin coadministration safety study sitagliptin és simvastatin egyidejű alkalmazásának biztonságossági vizsgálata
1. To assess the effect of MK-0431D compared to sitagliptin alone on A1C. 2. To assess the safety and tolerability of MK-0431D.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC. Estudio de fase III de carboplatino y paclitaxel o paclitaxel unido a albúmina en nanopartículas (nab-paclitaxel), con o sin pembrolizumab, en el CPNM epidermoide y metastásico en primera línea de tratamiento
In subjects with metastatic squamous non-small cell lung cancer (NSCLC) receiving investigator’s choice of standard of care chemotherapy (i.e. carboplatin and a taxane): 1. To evaluate progression fre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
IMI/REL (MK-7655A) vs. CMS + IMI in Subjects with Imipenem-Resistant Bacterial Infection
(1) To estimate the proportion of subjects with favorable overall response to IMI/MK-7655 (Treatment Group 1 only) and to CMS + IMI (Treatment Group 2). The overall response will be estimated based o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pediatric Asthma Safety Study
To estimate the effects on HPA axis function for MF/F MDI 50/10 mcg, 100/10 mcg and 200/10 mcg twice daily (BID) in plasma cortisol AUC(0-24 hours) as compared to montelukast 5 mg once daily (QD) (4 m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer
To determine the efficacy of the combination of ridaforolimus and bicalutamide compared to placebo and bicalutamide by PSA decline within 12 weeks, a surrogate measurement of overall survival efficacy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A study in adults who have ongoing asthma, using a new product combined with Montelukast
The purpose of this study is to assess the efficacy and safety of MK-1029, compared with placebo, in subjects aged 18 to 75 years with evidence of asthma uncontrolled on montelukast, using measures of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Assess the effect of switching HIV-1 infected subjects with CNS toxicity (≥ Grade 2) from ATRIPLA™ or its complements to MK-1439A
To evaluate the effect of a switch to MK-1439A compared with continuation of ATRIPLA on the incidence of Grade 2 or worse CNS toxicity (defined as at least one toxicity listed on the CNS toxicity ques...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pediatric Dose-Ranging of Mometasone Furoate MDI
To demonstrate the dose-related efficacy by evaluating morning lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second [FEV1]) after 12 we...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Pembrolizumab in advanced renal cell carcinoma
1. To estimate the objective response rate (ORR) per RECIST 1.1 as assessed by BICR in subjects with clear cell RCC. 2. To estimate the ORR per RECIST 1.1 as assessed by BICR in subjects with non-cle...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co
MAJ Il y a 4 ans
A Study of Sitagliptin/Metformin in Pediatric Patients with Type 2 Diabetes Mellitus not Controlled on Metformin
Base and extension study Over 20 weeks (base) and over 54 weeks (extension)-assess safety and tolerability of the addition of sitagliptin (as MK-0431A) in pediatric patients (10-17 y.) with T2DM wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant